LIVIVO - Search results -

Search results

Result 1 - 10 of total 119

Search options

Article: Sabit doz inhale kortikosteroid, uzun etkili beta-2 agonist ve uzun etkili muskarinik reseptör antagonisti (İKS/LABA/LAMA) kombinasyonunun astım tedavisindeki yer.

Ünsay Metan, Esra / Bavbek, Sevim

2021 Volume 69, Issue 3, Page(s) 369–379

Abstract: The effective treatment of asthma is important in terms of improving the quality of life and decreasing the number of hospital admissions due to acute exacerbations. Parasymphatic activity is increased in patients with asthma. This is one of most ... ...

Title translation	The role of fixed dose combinations of inhaled cortikosteroids, long acting beta-2 agonists, and long acting muscarinic antagonists (ICS/LABA/LAMA) in the treatment of asthma.
Abstract	The effective treatment of asthma is important in terms of improving the quality of life and decreasing the number of hospital admissions due to acute exacerbations. Parasymphatic activity is increased in patients with asthma. This is one of most important part of airway obstruction which has a great potential for reversibility. The evidence about the synergic interaction between inhaled corticosteroids (ICS), long acting beta-2 agonists (LABA), and long acting muscarinic antagonists (LAMA) encourages the use of LAMA in asthma. Tiotropium treatment was found to be successful in patients with recurrent exacerbations in whom asthma was uncontrolled despite treatment with other add on treatments that were recommended at GINA step 4. These findings triggered several clinical studies on fixed dose ICS/LABA/LAMA for asthma treatment. Three studies that have been published recently showed that fixed dose ICS/LABA/LAMA improved the lung functions and decreased the exacerbation rate without increasing the dose of ICS or LABA in asthma. In this review, the mechanisms of action of LAMA in asthma were summarized and possible role of fixed dose ICS/LABA/ LAMA in asthma treatment was discussed under the light of current literature.
MeSH term(s)	Administration, Inhalation ; Adrenal Cortex Hormones/therapeutic use ; Adrenergic beta-2 Receptor Agonists/therapeutic use ; Asthma/drug therapy ; Humans ; Muscarinic Antagonists/therapeutic use ; Quality of Life
Chemical Substances	Adrenal Cortex Hormones ; Adrenergic beta-2 Receptor Agonists ; Muscarinic Antagonists
Language	Turkish
Publishing date	2021-09-27
Publishing country	Turkey
Document type	Journal Article ; Review
ZDB-ID	2468802-2
ISSN	0494-1373
ISSN	0494-1373
DOI	10.5578/tt.20219709
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6702: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri.

Cengiz, Ali / Bavbek, Sevim

Tuberkuloz ve toraks

2021 Volume 69, Issue 2, Page(s) 261–268

Abstract: Asthma is a heterogeneous lung disease characterized by chronic airway inflammation. It was suggested that patients with mild asthma symptoms could be managed with as-needed short-acting β2-agonists (SABA) in previous years. In 2019, GINA made a radical ... ...

Title translation	GINA 2019 - step 1 and 2 treatment in asthma: Updates with reasons behind.
Abstract	Asthma is a heterogeneous lung disease characterized by chronic airway inflammation. It was suggested that patients with mild asthma symptoms could be managed with as-needed short-acting β2-agonists (SABA) in previous years. In 2019, GINA made a radical change and recommended that SABA should not be used as monotherapy in patients with mild asthma, but instead as-needed low-dose inhaled corticosteroid (ICS)-formoterol or "additional low-dose ICS taken whenever SABA is taken" treatments should be commenced to relieve and control symptoms. The approach emerged in the light of the studies that indicate the increased risk of severe exacerbation and asthma-related death due to overuse of SABA. The present article aimed to enlighten the updates in GINA 2019 step 1 and 2 treatment, the grounds for these updates with the supportive studies.
MeSH term(s)	Adrenergic beta-Antagonists/administration & dosage ; Adrenergic beta-Antagonists/adverse effects ; Adrenergic beta-Antagonists/therapeutic use ; Anti-Asthmatic Agents/administration & dosage ; Anti-Asthmatic Agents/adverse effects ; Anti-Asthmatic Agents/therapeutic use ; Asthma/drug therapy ; Humans ; Prescription Drug Overuse
Chemical Substances	Adrenergic beta-Antagonists ; Anti-Asthmatic Agents
Language	Turkish
Publishing date	2021-07-10
Publishing country	Turkey
Document type	Journal Article
ZDB-ID	2468802-2
ISSN	0494-1373
ISSN	0494-1373
DOI	10.5578/tt.20219817
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6702: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Apples and pears serve the same purpose: Better diagnosis for anaphylaxis.

Çolak, Sevgi / Erkoç, Merve / Sin, Betül A / Bavbek, Sevim

The World Allergy Organization journal

2023 Volume 16, Issue 10, Page(s) 100822

Language	English
Publishing date	2023-10-06
Publishing country	United States
Document type	Journal Article
ZDB-ID	2581968-9
ISSN	1939-4551
ISSN	1939-4551
DOI	10.1016/j.waojou.2023.100822
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Comparison of two diagnostic criteria in the diagnosis of anaphylaxis in a tertiary adult allergy clinic.

Çolak, Sevgi / Erkoç, Merve / Sin, Betül A / Bavbek, Sevim

The World Allergy Organization journal

2023 Volume 16, Issue 3, Page(s) 100761

Abstract: Background: Anaphylaxis is a very dynamic issue with its incidence and trigger profile changing over the years. We aimed to compile the characteristics of anaphylaxis cases diagnosed in our clinic prospectively and to make a comparison between ... ...

Abstract	Background: Anaphylaxis is a very dynamic issue with its incidence and trigger profile changing over the years. We aimed to compile the characteristics of anaphylaxis cases diagnosed in our clinic prospectively and to make a comparison between diagnostic criteria proposed by National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network (NIAID/FAAN) and World Allergy Organization (WAO). Method: Three-item diagnostic criteria recommended by NIAID/FAAN (2006) were used in the diagnosis of anaphylaxis. The clinical features of the cases, risk factors, etiologies, severity of anaphylaxis, and treatment approach were determined. The same patients were also classified by current WAO diagnostic criteria. Results: A total of 204 patients (158F/46 M, median age 45.3 years) were included. Drugs (65.2%), venom (9.8%) and food allergies (9.3%) were the top 3 etiologies. Among drug triggers, chemotherapeutics were the most common (17.7%), followed by antibiotics (15.3%) and non-steroidal anti-inflammatory drugs (14.2%). The patients were mostly diagnosed with the second criterion (84.8%), followed by the first criterion (11.8%) and the third criterion (3.4%) of the NIAID/FAAN criteria. In terms of WAO criteria, 82.8% of the patients were diagnosed with the first criterion, and 14.3% with the second criterion while 2.9% of the patients did not meet the WAO criteria. The severity of anaphylaxis was evaluated as grade-2, 3 and 4 in 30.9%, 64.2%, and 4.9% of the patients, respectively. Adrenaline was administered to 31.9% of the patients especially who had angioedema and bronchospasm (p = 0.04). Conclusion: Our data suggest that covering more details in patient's history may prevent possible underdiagnosis and WAO diagnostic criteria seem to be insufficient in some patients. We believe that our results will contribute to the literature on anaphylaxis and would be groundwork for future studies.
Language	English
Publishing date	2023-04-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	2581968-9
ISSN	1939-4551
ISSN	1939-4551
DOI	10.1016/j.waojou.2023.100761
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Rituximab Hypersensitivity: From Clinical Presentation to Management.

Fouda, Ghada E / Bavbek, Sevim

Frontiers in pharmacology

2020 Volume 11, Page(s) 572863

Abstract: Rituximab is a chimeric monoclonal antibody (mAb) against CD20 molecule which is expressed on human B cells. It has been used for the treatment of various lymphoid malignancies, lymphoproliferative diseases, and rheumatologic disorders. Rituximab is ... ...

Abstract	Rituximab is a chimeric monoclonal antibody (mAb) against CD20 molecule which is expressed on human B cells. It has been used for the treatment of various lymphoid malignancies, lymphoproliferative diseases, and rheumatologic disorders. Rituximab is generally well tolerated. However, increased use of rituximab has been associated with hypersensitivity reactions (HSRs), which can be classified as infusion-related, cytokine-release, type I (IgE/non-IgE), mixed, type III, and type IV reactions. Immediate infusion-related reactions to rituximab are quite common and decrease in frequency with subsequent infusions. However, in about 10% of patients, severe infusion-related reactions develop, which prevent its use. Some of the immediate infusion reactions are due to a cytokine-release but some reactions raise concerns for type I (IgE/non-IgE) hypersensitivity. Recent studies have shown the presence of serum anti-rituximab antibodies, either represented by the IgG or IgE isotype. In some cases, clinical manifestations of IgE-mediated reactions and cytokine-release reactions partially overlap, which is called a mixed reaction. Classified as Type III reaction, rituximab-induced serum sickness reactions have been reported in patients with autoimmune diseases and hematological malignancies. The classic serum sickness triad (fever, rash, and arthralgia) has been observed in patients mainly with an underlying rheumatologic condition. Severe delayed type IV hypersensitivity reactions including non-severe maculopapular rash to severe reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been rarely reported following rituximab injection. Comprehensive reviews focused on rituximab-induced HSRs are scarce. We aimed to review clinical presentations, underlying mechanisms of rituximab hypersensitivity, as well as management including rapid drug desensitization.
Language	English
Publishing date	2020-09-08
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2020.572863
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Ağır eozinofilik astımda anti-IL-5 tedaviler: gerçek yaşam verileri.

Özdel Öztürk, Betül / Bavbek, Sevim

Tuberkuloz ve toraks

2020 Volume 68, Issue 2, Page(s) 148–159

Abstract: Randomized controlled studies have shown that anti-IL-5 treatments reduce the need for oral corticosteroids, annual asthma exacerbation and hospitalization rates, blood eosinophil count and increase FEV1 values, asthma control, and quality of life in ... ...

Title translation	Anti-IL-5 treatments in severe eosinophilic asthma: real life datas.
Abstract	Randomized controlled studies have shown that anti-IL-5 treatments reduce the need for oral corticosteroids, annual asthma exacerbation and hospitalization rates, blood eosinophil count and increase FEV1 values, asthma control, and quality of life in patients with eosinophilic severe asthma. Although the number of real-life studies with anti-IL-5 is limited, there are 10 real life studies with mepolizumab, one real life study with benralizumab and one real life study with reslizumab in the current literature. Similar to randomized controlled trials, real-life studies reported that a reduction in the need for oral corticosteroids, annual asthma exacerbation and hospitalization rates, and blood eosinophil counts and increase FEV1 values, asthma control test and quality of life scores, Response criteria were defined in some of the real-life studies and although different response rates were given according to these criteria, most of the patients with severe eosinophilic asthma showed high response rates to anti-IL-5 treatments. In real-life studies evaluating the safety of anti-IL-5 treatments, the most common adverse effect is mild local injection site reaction that does not require treatment, in conclusion, real-life studies suggest that all three anti-IL-5 treatments in clinical practice are effective and well tolerated.
MeSH term(s)	Adrenal Cortex Hormones/therapeutic use ; Adult ; Anti-Asthmatic Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Asthma/drug therapy ; Female ; Humans ; Interleukin-5/therapeutic use ; Leukocyte Count ; Male ; Pulmonary Eosinophilia/drug therapy ; Quality of Life ; Randomized Controlled Trials as Topic
Chemical Substances	Adrenal Cortex Hormones ; Anti-Asthmatic Agents ; Antibodies, Monoclonal, Humanized ; IL5 protein, human ; Interleukin-5 ; reslizumab (35A26E427H) ; benralizumab (71492GE1FX) ; mepolizumab (90Z2UF0E52)
Language	Turkish
Publishing date	2020-08-04
Publishing country	Turkey
Document type	Journal Article
ZDB-ID	2468802-2
ISSN	0494-1373
ISSN	0494-1373
DOI	10.5578/tt.69416
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6702: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Hypersensitivity reactions to proton-pump inhibitors: Clinical presentation, diagnosis, and management.

Kepil Özdemir, Seçil / Bavbek, Sevim

Allergy and asthma proceedings

2020 Volume 41, Issue 2, Page(s) e37–e44

Abstract: Background: ...

Abstract	Background:
MeSH term(s)	Anaphylaxis/diagnosis ; Anaphylaxis/therapy ; Animals ; Drug Hypersensitivity/diagnosis ; Drug Hypersensitivity/drug therapy ; Edema ; Eosinophilia ; Humans ; Proton Pump Inhibitors/adverse effects ; Proton Pump Inhibitors/therapeutic use ; Skin/pathology ; Skin Tests ; Urticaria
Chemical Substances	Proton Pump Inhibitors
Language	English
Publishing date	2020-03-03
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1312445-6
ISSN	1539-6304 ; 1088-5412
ISSN (online)	1539-6304
ISSN	1088-5412
DOI	10.2500/aap.2020.41.190033
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1804: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: ABPA’lı hastalarda biyolojik tedaviler.

Erkoç, Merve / Aydın, Ömür / Bavbek, Sevim

Tuberkuloz ve toraks

2021 Volume 69, Issue 1, Page(s) 84–93

Abstract: Allergic Bronchopulmonary Aspergillosis (ABPA) is a pulmonary disease characterized by recurrent pulmonary opacities and bronchiectasis caused by Type 1 hypersensitivity to A. fumigatus. Asthma is an important part of the disease and is generally in ... ...

Title translation	Biological Treatments in patients with ABPA.
Abstract	Allergic Bronchopulmonary Aspergillosis (ABPA) is a pulmonary disease characterized by recurrent pulmonary opacities and bronchiectasis caused by Type 1 hypersensitivity to A. fumigatus. Asthma is an important part of the disease and is generally in severe form. It is thought that immunoglobulins against A. fumigatus, Th2-derived cytokines such as IL-4, IL-5 and IL-13 and eosinophilic inflammation play a role in the pathogenesis of the disease. Monoclonal antibody treatments targeting IL-4, IL-5, IL-13 and IgE, which are involved in pathogenesis, have been used in asthmatic patients before. The main treatment of ABPA for exacerbations and remissions is oral corticosteroids (OCS). However, in cases where the corticosteroid dose cannot be reduced or side effects develop, monoclonal agents may be added to the treatment. Monoclonal agents such as omalizumab, mepolizumab, benralizumab and dupilumab targeting cytokines involved to the patogenesis have been used in patients with ABPA. Omalizumab has shown a reduction in exacerbations and OCS requirements, improvement in asthma symptoms and improvement in pulmonary function parameters. With mepolizumab, a decrease in OCS dose, decrease in blood eosinophil count, clinical improvement and radiological improvement were observed. Benralizumab reduced, the number of eosinophil or even almost nullified as well as clinical recovery alongside with radiological improvement. With dupilumab, improvement in symptoms, discontinuation of OCS, but increase in eosinophil count at the beginning of treatment was reported. As a result, monoclonal antibodies were generally found to be successful and safe in patients with ABPA.
MeSH term(s)	Adrenal Cortex Hormones/therapeutic use ; Anti-Allergic Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Aspergillosis, Allergic Bronchopulmonary/diagnosis ; Aspergillosis, Allergic Bronchopulmonary/drug therapy ; Aspergillosis, Allergic Bronchopulmonary/microbiology ; Aspergillus fumigatus/isolation & purification ; Asthma/drug therapy ; Female ; Humans ; Lung/physiopathology ; Male ; Omalizumab/therapeutic use
Chemical Substances	Adrenal Cortex Hormones ; Anti-Allergic Agents ; Antibodies, Monoclonal, Humanized ; Omalizumab (2P471X1Z11) ; mepolizumab (90Z2UF0E52)
Language	Turkish
Publishing date	2021-04-14
Publishing country	Turkey
Document type	Journal Article
ZDB-ID	2468802-2
ISSN	0494-1373
ISSN	0494-1373
DOI	10.5578/tt.20219910
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6702: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Özelleşmiş bir astım polikliniğinin ağır astım verileri.

Çelebi Sözener, Zeynep / Özdel Öztürk, Betül / Aydın, Ömür / Mungan, Dilşad / Bavbek, Sevim

Tuberkuloz ve toraks

2023 Volume 71, Issue 2, Page(s) 156–165

Abstract: Introduction: In patients with severe asthma, individualized treatment, and appropriate phenotyping are required to achieve control. In our study, our aim was to examine the characteristics of a specific patient group in a specialized tertiary asthma ... ...

Title translation	The profile of severe asthmatics: Results from a specialized asthma clinic.
Abstract	Introduction: In patients with severe asthma, individualized treatment, and appropriate phenotyping are required to achieve control. In our study, our aim was to examine the characteristics of a specific patient group in a specialized tertiary asthma outpatient clinic, which is the primary setting for evaluating severe asthma patients, with the intention of obtaining national data. Materials and methods: In this cross-sectional observational study, sociodemographic, clinical presentations, laboratory results, and spirometry measurements of patients with severe asthma who were followed up in our specialized asthma outpatient clinic for at least one year were recorded. Patients were defined as eosinophilic if they had a blood eosinophil count of 300/µL or higher at least twice during the oral corticosteroid free-period or 150/µL or higher under oral corticosteroids as allergic if they had sensitization to at least one inhalant allergen consistent with their history. Result: Overall, 201 severe asthma patients (74.1% female) with a median disease duration of 15 (min-max= 1-49) years and a median follow-up duration of 7 (min-max= 1-40) years were analyzed. Most of the patients (56.7%) had adult-onset asthma [median age of onset was 32 (min-max= 10-62) years]. Overweight and obese patients were in the majority (31.8%, and 41.8%, respectively) and the median body mass index was 29 (min-max= 17.5-49.5). More than half of the patients (55.2%) had controlled asthma and the median Asthma Control Test score at the last visit was 23. Biologic therapies were applied to 73.1% (n= 147) of the patients [60.5% (n= 89) omalizumab, 39.5% (n= 58) mepolizumab]. Half of the group was allergic (49.3%) and three-quarters of them were eosinophilic (72.1%). Allergic patients had earlier asthma onset and had more controlled disease than nonallergic ones. Eosinophilic patients were younger and less obese than noneosinophilic patients. Obese and late-onset asthmatics had more uncontrolled disease than normal weight subjects and early onset patients. Conclusions: The high rate of disease control in the patients with severe asthma in the current study demonstrated the importance of targeted individualized therapy with accurate phenotyping in specialized asthma outpatient clinics.
MeSH term(s)	Adult ; Humans ; Female ; Child ; Adolescent ; Young Adult ; Middle Aged ; Male ; Anti-Asthmatic Agents/therapeutic use ; Cross-Sectional Studies ; Asthma/drug therapy ; Omalizumab/therapeutic use ; Adrenal Cortex Hormones/therapeutic use ; Obesity
Chemical Substances	Anti-Asthmatic Agents ; Omalizumab (2P471X1Z11) ; Adrenal Cortex Hormones
Language	Turkish
Publishing date	2023-06-21
Publishing country	Turkey
Document type	Observational Study ; English Abstract ; Journal Article
ZDB-ID	2468802-2
ISSN	2980-3187 ; 0494-1373
ISSN (online)	2980-3187
ISSN	0494-1373
DOI	10.5578/tt.20239919
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6702: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online ; Conference proceedings: Turkish Thoracic Society 16th Annual Congress: while I breathe, I hope.

Bavbek, Sevim

Expert review of respiratory medicine

2013 Volume 7, Issue 5, Page(s) 447–449

Abstract: Turkish Thoracic Society Meeting Antalya, Turkey, 3-7 April 2013 This year, the 16th Annual Congress of Turkish Thoracic Society took place in Antalya, Turkey, on 3-7 April 2013. The Turkish Thoracic Society has successfully organized 15 congresses ... ...

Abstract	Turkish Thoracic Society Meeting Antalya, Turkey, 3-7 April 2013 This year, the 16th Annual Congress of Turkish Thoracic Society took place in Antalya, Turkey, on 3-7 April 2013. The Turkish Thoracic Society has successfully organized 15 congresses starting in 1996, but it has been held annually since 2000. Considerable effort, dedication and enthusiasm behind the scenes are the major reasons for the national success and high quality of the congress. Each national congress of the Turkish Thoracic Society represents an outstanding collaboration between headquarters and the chief committee, all the members, specialists, residents and sponsors. It was officially reported that this year the congress had attracted over 1500 participants from different parts of Turkey along with 23 international faculties. A total of 815 abstracts have been sent to the scientific program committee and 153 abstracts among them have been accepted as oral presentations and the remaining have ended up as poster presentation.
MeSH term(s)	Asthma/diagnosis ; Asthma/physiopathology ; Asthma/therapy ; Biomedical Research ; Cooperative Behavior ; Humans ; International Cooperation ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Pulmonary Disease, Chronic Obstructive/therapy ; Pulmonary Medicine ; Societies, Medical ; Turkey
Language	English
Publishing date	2013-10
Publishing country	England
Document type	Congresses
ZDB-ID	2479146-5
ISSN	1747-6356 ; 1747-6348
ISSN (online)	1747-6356
ISSN	1747-6348
DOI	10.1586/17476348.2013.837745
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6963: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito